Page 2 - Russian Gamaleya Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Russian gamaleya research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Russian Gamaleya Research Today - Breaking & Trending Today

Sputnik V-AstraZeneca Covid-19 Vaccines' Joint Trials to Start Soon


Sputnik V-AstraZeneca Covid-19 Vaccines Joint Trials to Start Soon
©
AP Photo / Alexander Zemlianichenko Jr
Subscribe
Sputnik International
https://sputniknews.com/world/202012171081493454-sputnik-v-astrazeneca-covid-19-vaccines-joint-trials-to-start-soon/
MOSCOW (Sputnik) - The joint clinical trials of the Russian Sputnik V vaccine and UK-Swedish AstraZeneca s vaccine against the coronavirus will start very soon, head of the research center that developed Sputnik V, Alexander Gintsburg said Thursday.
[Russian Direct Investment Fund] RDIF and AstraZeneca agreed to hold joint clinical trials, which would use Oxford-made component as the first injection, and Sputnik V component as the second one. As far as I understand, these trials will begin in the near future, Gintsburg said, as aired on Rossiya 24 broadcaster. ....

Orenburgskaya Oblast , United Kingdom , Alexander Gintsburg , Russian Gamaleya Research , Oxford University , United Kingdom Swedish , ஒன்றுபட்டது கிஂக்டம் , ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் , ஒன்றுபட்டது கிஂக்டம் ஸ்விட்ச் ,

Russian and British scientists team up to create Covid-19 vaccine


15 Dec 2020 in 8:20
Caspian News
British pharmaceutical giant AstraZeneca unveiled plans to collaborate with the developer of Russia s Sputnik V, the Moscow-based Gamaleya Research Institute of Epidemiology and Microbiology, and explore whether their two coronavirus vaccines could be successfully combined, Caspian News writes in the article 
Today we announce a clinical trial programme to assess safety and immunogenicity of combination of AZD1222, developed by AstraZeneca and Oxford University and Sputnik V, developed by Russian Gamaleya Research institute, AstraZeneca said on Friday in a statement issued on its website.
Russia was the first country to register a coronavirus vaccine in August despite Sputnik V s incomplete clinical trials. While the vaccine is yet to complete its third and final phase of testing involving some 40,000 volunteers, its developers revealed that interim trial results of the vaccine showed 95% efficacy. Russia s first vaccine, ....

United States , United Kingdom , Russia Direct Investment Fund , World Health Organization , Gamaleya Research Institute Of Epidemiology , Russian Gamaleya Research , Johns Hopkins Center , Oxford University , Moscow Based Gamaleya Research Institute , Caspian News , Sputnikv Developer Explore Possibility , Soviet Union , Direct Investment Fund , Systems Science , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ரஷ்யா நேரடி முதலீடு நிதி , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , ஜான்ஸ் ஹாப்கின்ஸ் மையம் , ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் , காஸ்பியன் செய்தி , சோவியத் தொழிற்சங்கம் , நேரடி முதலீடு நிதி , அமைப்புகள் அறிவியல் ,

AstraZeneca to test combination of AZD1222 and Sputnik V vaccines

AstraZeneca to test combination of AZD1222 and Sputnik V vaccines
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Kirill Dmitriev , Russian Gamaleya Research , Gamaleya Institute , Oxford University , Russian Direct Investment Fund , ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் , ரஷ்ய நேரடி முதலீடு நிதி ,

Russia's coronavirus vaccine has efficacy of 91.4%, trial results suggest


Russia’s coronavirus vaccine has efficacy of 91.4%, trial results suggest
PA
14 December 2020, 2:51 pm
Russia’s coronavirus vaccine is up to 91.4% effective at stopping people developing Covid-19 symptoms, according to its developers.
Interim phase three results of the Sputnik V vaccine trial were based on data from volunteers who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point.
The Russian Direct Investment Fund, the country’s sovereign wealth fund, said evaluation of efficacy was carried out among volunteers (22,714) 21 days after receiving the first dose of the vaccine or placebo. ....

Denis Logunov , Gamaleya Centre , University Of Oxford , Russian Gamaleya Research Institute , Russian Direct Investment Fund , Russian Gamaleya Research , பல்கலைக்கழகம் ஆஃப் ஆக்ஸ்ஃபர்ட் , ரஷ்ய நேரடி முதலீடு நிதி ,